Morgan Stanley analyst Michael Ulz has reiterated their bullish stance on VKTX stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ulz has given his Buy rating due to a combination of factors, primarily focusing on the promising progress of Viking Therapeutics’ clinical programs. The company’s Phase 3 VANQUISH studies for VK2735, targeting obesity and type-2 diabetes, are enrolling participants ahead of schedule, indicating strong operational execution and heightened interest in the trials. This accelerated enrollment suggests a positive outlook for the completion of these studies, with VANQUISH-1 expected to finish by the end of 2025 and VANQUISH-2 in the first quarter of 2026.
Additionally, Viking Therapeutics is advancing its oral VK2735 program, with plans to meet the FDA in the fourth quarter of 2025 to discuss further steps. Previous Phase 2 data for oral VK2735 showed encouraging weight loss results, which align with or exceed industry standards, and the company is working on improving tolerability. These developments, along with the anticipation of maintenance study data by mid-2026, contribute to the positive sentiment and the Buy rating for Viking Therapeutics’ stock.